je.st
news
Tag: findings
Experts Discuss Recent Findings in PEDv Monitoring, Risk Factors and Immunology
2015-06-29 02:00:00| ThePigSite - Industry News
US - With the recent increase in porcine epidemic diarrhea virus (PEDv) cases reported this spring, the latest At The Meeting (ATM) with the Morrison Group audio program provides an update on developments in case reporting, effective control steps and immunology in the last year.
Tags: recent
risk
factors
discuss
Pearl District | 5/27/2015 | 1241 NW Johnson St | Design Review w/ Modifications - Council Findings | LU 14-230014 DZM
2015-06-22 22:41:22| PortlandOnline
PDF Document, 381kbCategory: Neighbors West/Northwest Decisions
Tags: design
review
district
council
Proof from the Field: Findings of data analysis show advantage of PCV2 vaccine
2015-06-04 14:40:23| National Hog Farmer
By Brad Thacker, D.V.M., Ph.D., MBA, senior technical services veterinarian, Merck Animal Health Evaluating vaccination protocols in real-world situations is important to helping producers and veterinarians make decisions that will optimize the health of their pigs along with the profitability of their operations. It’s not often, though, that data from an independent operation involving nearly a half-million pigs can be obtained and analyzed to provide reliable performance and economic information. Such is the case involving a Midwest operation. read more
Tags: show
data
field
analysis
IARC herbicide findings create confusion, fear
2015-06-02 22:20:00| Corn & Soybean Digest
Source: NCGA, ASA NCGA and ASA are concerned that a pending announcement from the U.N. World Health Organizations International Agency for Research on Cancer will only lead to more confusion and concern about two widely-used herbicides that have been mainstays for farmers for decades. These two substances play an especially important role in corn and soybean farming as they allow us to manage weeds in a sustainable way. read more
Tags: create
fear
findings
confusion
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
Sites : [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] next »